India Pharma Outlook Team | Thursday, 29 January 2026
RPG Life Sciences has shown strong support for the India–EU Free Trade Agreement (FTA), especially with respect to the proposed tariff drop to 11 percent on pharmaceutical products.
The firm feels that this will go a long way in enhancing the competitiveness of the Indian pharmaceutical companies in the European market, as well as enhancing access to quality and affordable medicine to patients.
Ashok Nair, Managing Director of RPG Life Sciences, stated, “The India–EU Free Trade Agreement, with removal of 11% tariff on pharmaceutical products, is a welcome development for the pharmaceutical sector and a decisive step in strengthening India’s position as a trusted global healthcare partner.
It comes at a critical time, as global healthcare systems are actively looking to diversify and de-risk their supply chains, and India is uniquely positioned to address this need.”
Nair further emphasized that the agreement would open new opportunities for India to scale exports, expand product portfolios, and foster long-term partnerships with European healthcare systems.
He added, “Besides significantly improving the cost competitiveness of Indian medicines in Europe, it creates a strong incentive for Indian companies to invest in quality, compliance, and innovation aligned with global standards.”
As the FTA could help enhance trade relationships, RPG Life Sciences considers this as one of the most important moves towards increased investments in areas like R&D, capacity building, and employment in India, as well as making sure that European patients have access to cheap pharmaceutical alternatives.
.jpg)
